“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Carmat
Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. Management is taking corrective actions with recent quality challenges.
Carmat — 4 videos in collection
Carmat is French biotech company that has created the first auto-regulating, bioprosthetic artificial heart able to mimic the natural physiology of the human heart. The company’s mission is to provide cardiologists with innovative technologies that save lives and improve the quality of life for patients with advanced heart failure.
In this Edison executive interview, Vivienne Parry, science journalist, author and head of engagement at Genomics England meets with Carmat CEO, Stéphane Piat, to discuss the company’s transformative year, recent CE mark verification and upcoming milestone achievements anticipated for the EFICAS and US feasibility studies in 2021.
Get access to the very latest content matched to your personal investment style.
